[
  {
    "ts": null,
    "headline": "Akeso survival data for ivonescimab misses expectations, STAT says",
    "summary": "While Akeso (AKESF) and Summit Therapeutics’ (SMMT) ivonescimab, a rival to Merck’s (MRK) Keytruda, won approval in China this week, the data on patient survival did not meet analyst expectations, Jonathan Wosen of STAT reports. In its submission to regulators, Akeso included data on patient survival, disclosing that an interim analysis following 157 patient deaths found that participants on ivonescimab had a roughly 22% reduced risk of death, with a hazard ratio of 0.784, a company spokesperson",
    "url": "https://finnhub.io/api/news?id=bacf50516027125516c94027c9fd98eaa6769588d2e16fb0868bb51f4f49c6a0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745686217,
      "headline": "Akeso survival data for ivonescimab misses expectations, STAT says",
      "id": 134104556,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "While Akeso (AKESF) and Summit Therapeutics’ (SMMT) ivonescimab, a rival to Merck’s (MRK) Keytruda, won approval in China this week, the data on patient survival did not meet analyst expectations, Jonathan Wosen of STAT reports. In its submission to regulators, Akeso included data on patient survival, disclosing that an interim analysis following 157 patient deaths found that participants on ivonescimab had a roughly 22% reduced risk of death, with a hazard ratio of 0.784, a company spokesperson",
      "url": "https://finnhub.io/api/news?id=bacf50516027125516c94027c9fd98eaa6769588d2e16fb0868bb51f4f49c6a0"
    }
  },
  {
    "ts": null,
    "headline": "Merck First Quarter 2025 Earnings: Beats Expectations",
    "summary": "Merck ( NYSE:MRK ) First Quarter 2025 Results Key Financial Results Revenue: US$15.5b (down 1.6% from 1Q 2024). Net...",
    "url": "https://finnhub.io/api/news?id=08d8a27f9550348da60c10bd4e5ed4c0e4bbffd4e3687a5f3d8373206f81864b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745672449,
      "headline": "Merck First Quarter 2025 Earnings: Beats Expectations",
      "id": 134104557,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck ( NYSE:MRK ) First Quarter 2025 Results Key Financial Results Revenue: US$15.5b (down 1.6% from 1Q 2024). Net...",
      "url": "https://finnhub.io/api/news?id=08d8a27f9550348da60c10bd4e5ed4c0e4bbffd4e3687a5f3d8373206f81864b"
    }
  },
  {
    "ts": null,
    "headline": "Summit Therapeutics: New Ivonescimab Data Raise Concerns",
    "summary": "Summit Therapeutics' shares dropped 36% after ivonescimab data showed no significant survival benefit. Click to read if SMMT is a Hold or a Sell.",
    "url": "https://finnhub.io/api/news?id=92bceb505c1aee24c404474d888a9c2323eadb0e7d1a36fd0ffa7b1d3a24be3b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745659800,
      "headline": "Summit Therapeutics: New Ivonescimab Data Raise Concerns",
      "id": 134099846,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2181270761/image_2181270761.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Summit Therapeutics' shares dropped 36% after ivonescimab data showed no significant survival benefit. Click to read if SMMT is a Hold or a Sell.",
      "url": "https://finnhub.io/api/news?id=92bceb505c1aee24c404474d888a9c2323eadb0e7d1a36fd0ffa7b1d3a24be3b"
    }
  }
]